PharmaShots Weekly Snapshots (February 28- March 04, 2022)
Published: Mar 04, 2022 | Tags: Amgen, Lumykras, sotorasib NICE, Recommendation, Non-Small-Cell Lung Cancer
Published: Mar 04, 2022 | Tags: Fulcrum, P-III, REACH Trial, Losmapimod, Facioscapulohumeral Muscular Dystrophy
Published: Mar 04, 2022 | Tags: Aravive, Batiraxcept, P-Ib Study, Clear Cell Renal Cell Carcinoma
Published: Mar 04, 2022 | Tags: AstraZeneca, Sanofi, Nirsevimab, P-III, MELODY Trial, RSV, NEJM
BeiGene’s Brukinsa (zanubrutinib) Receives the Health Canada Approval for the Treatment of Marginal Zone Lymphoma
Published: Mar 04, 2022 | Tags: BeiGene, Brukinsa, zanubrutinib, Health Canada, Approval, Marginal Zone Lymphoma
Published: Mar 04, 2022 | Tags: Aquestive, Haisco, Exservan, riluzole oral film, ALS, China
Published: Mar 03, 2022 | Tags: Pfizer, US, FDA, Breakthrough Therapy Designation, Respiratory Syncytial Virus Vaccine, RSV
Published: Mar 03, 2022 | Tags: Lexeo, LX1001, P-I/II, Clinical Trial, Alzheimer’s Disease
SAB Biotherapeutics Discontinues P-III (ACTIV-2) Trial of SAB-185 for the Treatment of COVID-19
Published: Mar 03, 2022 | Tags: SAB Biotherapeutics, P-III, ACTIV-2 Trial, SAB-185, COVID-19
Published: Mar 03, 2022 | Tags: AmMax Bio, AMB-05X, P-II, POC Study, Tenosynovial Giant Cell Tumor
Published: Mar 03, 2022 | Tags: Novartis, Kesimpta, ofatumumab, P-IIIb, ALITHIOS, OLE Study, Multiple Sclerosis
Published: Mar 03, 2022 | Tags: Oculis, Accure Therapeutics, ACT-01, Acute Optic Neuritis, Glaucoma
Published: Mar 02, 2022 | Tags: Adagene, Sanofi, Masked Immuno-Oncology Antibody
Published: Mar 02, 2022 | Tags: Medexus, NXDC, Gleolan, Glioma, US
Published: Mar 02, 2022 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, P-III, EMPULSE Trial, Acute Heart Failure
Published: Mar 02, 2022 | Tags: Pfizer, Clostridioides Difficile Vaccine, P-III, CLOVER Trial, C. Difficile Infection
Published: Mar 02, 2022 | Tags: Quanterix, Eli Lilly, Plasma-Based Biomarkers, Alzheimer’s Disease
AbbVie Acquires Syndesi Therapeutics for ~$1B
Published: Mar 02, 2022 | Tags: AbbVie, Acquires, Syndesi Therapeutics, ~$1B, Neuropsychiatric, Neurodegenerative Disorders, Alzheimer's disease
Published: Mar 01, 2022 | Tags: Legend Biotech, Carvykti, ciltacabtagene autoleucel, US, FDA, Approval, Multiple Myeloma
Published: Mar 01, 2022 | Tags: Goldfinch Bio, GFB-887, P-II, TRACTION-2 Trial, Focal Segmental Glomerular Sclerosis, Diabetic Nephropathy
Published: Mar 01, 2022 | Tags: Innovent, AnHeart, NMPA, Breakthrough Therapy Designation, Taletrectinib, ROS1-Positive. Non-Small Cell Lung Cancer
Published: Mar 01, 2022 | Tags: Crinetics, Sanwa Kagaku Kenkyusho, Paltusotine, Japan, Acromegaly, Neuroendocrine Tumors
Blueprint Collaborated with Proteovant to Advance Novel Targeted Protein Degrader Therapies
Published: Mar 01, 2022 | Tags: Blueprint, Proteovant, Protein Degrader Therapies
Biocon to Acquire Viatris’ Biosimilars Assets for ~$3.335B
Published: Mar 01, 2022 | Tags: Biocon, Acquire, Viatris, Biosimilars, ~$3.335B
Published: Feb 28, 2022 | Tags: Sanofi, AAAAI, Dupixent, Eosinophilic Esophagitis
Published: Feb 28, 2022 | Tags: Amgen, AAAAI, NAVIGATOR, PATHWAY, Tezspire
Published: Feb 28, 2022 | Tags: Clarity, P-I/IIa Study, CL04, Cu/67Cu Sartate, Neuroblastoma
Merck’s Keytruda + Lenvima Receives MHLW’s Approval in Japan to Treat Renal Cell Carcinoma
Published: Feb 28, 2022 | Tags: Merck, Keytruda, Lenvima, MHLW, Approval, Japan, Renal Cell Carcinoma
Published: Feb 28, 2022 | Tags: Sobi, Gamifant, emapalumab, Approval, China, CDE, Primary Haemophagocytic Lymphohistiocytosis
Biohaven to Acquire Channel Biosciences for ~$3B
Published: Feb 28, 2022 | Tags: Biohaven, Acquire, Channel Biosciences, ~$3B
Related Post: PharmaShots Weekly Snapshots (February 21-25, 2022)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com